Immunocore (NASDAQ:IMCR) PT Raised to $74.00 at Mizuho

Immunocore (NASDAQ:IMCR – Get Rating) had its target price boosted by research analysts at Mizuho from $70.00 to $74.00 in a research note issued to investors on Thursday, The Fly reports. Mizuho’s price objective points to a potential upside of 20.38% from the stock’s previous close.

IMCR has been the subject of several other research reports. Oppenheimer raised their price target on Immunocore from $65.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, February 15th. Guggenheim started coverage on Immunocore in a research report on Thursday, March 30th. They set a “buy” rating and a $85.00 target price for the company. Bryan, Garnier & Co started coverage on Immunocore in a report on Friday, March 24th. They issued a “buy” rating and a $16.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $90.00 price target on shares of Immunocore in a report on Wednesday, April 19th. Thirteen investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $73.33.

Immunocore Trading Up 4.4 %

Shares of IMCR opened at $61.47 on Thursday. Immunocore has a fifty-two week low of $26.12 and a fifty-two week high of $69.06. The company has a debt-to-equity ratio of 0.24, a quick ratio of 4.71 and a current ratio of 4.72. The firm has a market cap of $2.70 billion, a P/E ratio of -53.92 and a beta of 0.57. The business has a 50-day moving average of $54.03 and a 200 day moving average of $57.40.

Immunocore (NASDAQ:IMCR – Get Rating) last issued its quarterly earnings results on Wednesday, March 1st. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.64). Immunocore had a negative return on equity of 18.52% and a negative net margin of 29.57%. The firm had revenue of $58.04 million during the quarter, compared to analysts’ expectations of $49.11 million. As a group, research analysts forecast that Immunocore will post -1.26 EPS for the current year.

Hedge Funds Weigh In On Immunocore

Several large investors have recently modified their holdings of IMCR. Renaissance Technologies LLC acquired a new position in Immunocore in the first quarter worth approximately $218,000. Rhenman & Partners Asset Management AB lifted its position in Immunocore by 89.4% during the 1st quarter. Rhenman & Partners Asset Management AB now owns 170,472 shares of the company’s stock worth $5,097,000 after acquiring an additional 80,472 shares during the last quarter. Vident Investment Advisory LLC lifted its position in Immunocore by 20.0% during the 1st quarter. Vident Investment Advisory LLC now owns 36,811 shares of the company’s stock worth $1,101,000 after acquiring an additional 6,135 shares during the last quarter. Royal Bank of Canada bought a new position in shares of Immunocore during the 1st quarter worth about $79,000. Finally, Bank of America Corp DE increased its holdings in shares of Immunocore by 92.0% during the 1st quarter. Bank of America Corp DE now owns 6,832 shares of the company’s stock worth $204,000 after purchasing an additional 3,274 shares during the period. Institutional investors own 65.11% of the company’s stock.

Immunocore Company Profile

(Get Rating)

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers.